Summary. The effects of barbituric acid and phenobarbital upon carbohydrate metabolism in mice were compared. An intraperitoneal dose of 100 mg/kg of barbituric acid increased blood glucose concentrations during an intravenous glucose tolerance test, but did not alter the rate of glucose disappearance from the blood. Barbituric acid also antagonized the hypoglycemic effect of intravenously administered tolbutamide. The same dose of phenobarbital had no effect. An in vitro concentration of 100 ~tg/ml of barbituric acid decreased the responsiveness of isolated mouse pancreatic islets to glucose stimulation (3.0 mg/ml D-glucose). Again phenobarbital, 100 ~tg/ml, was without effect. The structural similarities between barbituric acid, tolbutamide and alloxan suggest that the effects observed in these experiments might reflect a competition for binding to reactive sites on or within the pancreatic B-cell.
on the pancreatic B-cell membrane [4] . Evidence in support of this hypothesis, however, is indirect and does not rule out the possible role of the known membrane stabilizing action of DPH.
The experiments reported in this communication were conducted to determine if barbituric acid, like DPH, decreases glucose tolerance and antagonizes the hypoglycemic effect of tolbutamide in mice. Barbituric acid is closely related to alloxan in chemical configuration, but it has never been reported to stabilize biological membranes. Phenobarbital was ineluded in these experiments because it is a barbituric acid derivative which possesses CNS depressant properties and stabilizes biological membranes.
Materials and Methods

a. Animals and Chemicals
Male Swiss albino mice (Laboratory Supply Company, Indianapolis, IN) weighing 20 to 30 g were used in all experiments. The animals were housed in groups of ten with free access to food and water. The mice were acclimatised to laboratory conditions for one week prior to experimentation.
Barbituric acid (98% purity, Aldrich Chemical Co.) and sodium phenobarbital (98% purity, Merck) were dissolved in saline immediately before use. Dglucose (Mallinckrodt) was dissolved in distilled water 24 h prior to use and tolbutamide sodium (Upjohn) was dissolved in pH 8.3 Tris buffer (50 mM). Regular bovine insulin (Lilly) was diluted with saline just prior to use. All solutions and suspensions were prepared at concentrations which allowed for the administration of volume doses of 10 ml/kg. Barbituric acid and phenobarbital were administered intraperitoneally, glucose and tolbutamide intravenously and insulin subcutaneously. 
d. In Vitro Experiments
Pancreatic islets were isolated by the collagenase method of Lacy and Kostianovsky [7] . Immediately after isolation the islets were incubated for 30 minat 37 ~ in Krebs-Ringer bicarbonate buffer supplemented with 0.3% bovine serum albumin and 0.6 mg/ml of D-glucose. After stabilization, groups of three islets were incubated for 90 min under an atmosphere of 95% oxygen and 5% carbon dioxide in 1.0 ml of fresh medium containing 100 ~xg/ml of either barbituric acid or phenobarbital and 3.0 mg/ml of D-glucose. Incubations were carried out in a Dubnoff metabolic shaker (60 oscillations/min).
e. Glucose and Insulin Assays
Blood samples were obtained by orbital sinus puncture and serum glucose concentrations were determined by a glucose oxidase method (Beckman Glucose Analyzer).
,~, Aliquots (0.1 ml) of the islet incubation medium were taken at 30 rain intervals and assayed for immunoreactive insulin (IRI) using a commercial kit (Amersham/Searle). Human insulin was used asthe insulin standard.
b. Glucose Tolerance Test
Mice were pretreated with 100 mg/kg of either barbituric acid or phenobarbital 60 min before the intravenous injection of 2.0 gm/kg of D-glucose. This high dose of glucose was found to be necessary in order to sustain elevated serum glucose concentrations.
Serum glucose concentrations were determined 15, 30, 60 120 and 150 min after glucose injection. The rate of glucose disappearance (K) was determined as described by Conard [5] for the glucose concentration to fall from the value at 15-minutes to one-half of that value. Glucose distribution space was estimated by the method of Ganda et al. [6] .
c. Tolbutamide and Insulin Injection
Mice were pretreated with 100 mg/kg of either barbituric acid or phenobarbital 60 min before the administration of either 75 mg/kg of tolbutamide or 0.25 unit of insulin. Serum glucose concentrations were determined immediately before and at several intervals after the administration of the hypoglycemic agents.
f. Statistical Analyses
Differences between mean serum glucose concentrations and glucose disappearance rates were assessed for significance by the use of Student's t test. The effects of barbituric acid and phenobarbital on glucose-stimulated insulin release from isolated pancreatic islets were compared by one way analysis of variance.
Results
a. Effect of Barb#uric Acid and Phenobarbital on Serum Glucose Concentration
The results presented in Figure 1 show that the 100 mg/kg dose of barbituric acid produced an insignificant rise in serum glucose concentration. The 300 mg/kg dose produced significant hyperglycemia, which persisted for at least two hours. Phenobarbital, at a dose of 100 mg/kg, had no effect. A higher dose of 300 mg/kg was lethal within three hours, so a direct comparison with barbituric acid was not possible.
b. Effect of Barbituric Acid and Phenobarbital on Intravenous Glucose Tolerance
The 100 mg/kg dose of barbituric acid resulted in a significant elevation of serum glucose concentrations 15, 30 and 60 rain after the intravenous injection of glucose (Tab. 1). The same dose of phenobarbital, however, was without effect. As shown in Table 1 , when glucose disappearance rates were estimated it was found that either barbituric acid or phenobarbital had no effect on the glucose disappearance rate, although barbituric acid produced a marked decrease in the glucose distribution space (7.68 + 0.4 ml compared with 12.6 +_ 1.2 ml in control mice).
c. Effect of Barbituric Acid and Phenobarbital on the Hypoglycemic Effect of Tolbutamide
The results shown in Table 2 demonstrate the pronounced effect of tolbutamide on serum glucose concentrations in control mice. A significant hypoglycemia developed within 30 min and persisted throughout the remainder of the experimental period. When tolbutamide was administered to barbituric acid pretreated mice, however, no hypolgycemia was observed. Pretreatment with phenobarbital, on the other hand, did not alter the magnitude of tolbutamide-induced hypoglycemia.
d. Effect of Barbituric Acid on the Hypoglycemic Effect of lnsulin
Pretreatment of mice with 100 mg/kg barbituric acid one hour before the administration of insulin did not antagonize the hypoglycemic effect of the hormone. One hour after insulin administration mean decreases in serum glucose of 102 and 107% were observed.
e. Effect of Barbituric Acid and Phenobarbital on Glucose-Stimulated Insulin Release from Isolated Mouse Pancreatic Islets
The results of this experiment are shown in Table 3 . Control islets exhibited a steady release of IRI during the entire incubation period, while barbituric acid exposed islets released detectable quantities of IRI during only the 30 and 60 min intervals. No release was observed between 60 and 90 rain. Over the entire incubation period IRI release by the barbituric acid exposed islets was only 40% of that released by controls (p < 0.01). Phenobarbital, on the other hand, did not significantly reduce glucose-stimulated IRI release during any of the time intervals tested.
Discussion
The effects of barbituric acid reported in this communication are similar to those which have been noted earlier for diphenylhydantoin [2, 3, 8, 9] . Both chemicals increase serum glucose concentrations during the glucose tolerance test, antagonize the hypoglycemic effect of tolbutamide and inhibit glucose-induced IRI release in vitro.
The structural similarities between alloxan, barbituric acid, tolbutamide and diphenylhydantoin have led to an earlier suggestion that the observed interactions may be reflections of competition for binding sites on the pancreatic B-cell membrane [1, 4] . All of these chemicals possess unsubstituted ureido groups in their structural configurations and the importance of this portion of the molecules of alloxan and diphenylhydantoin have been shown in earlier in vivo experiments [4, 10] .
The fact that DPH is known to stabilize biological membranes suggests that the pancreatic effect of the anticonvulsant may be a nonspecific reflection of this action. Stabilization of the B-cell membrane would be expected to inhibit both glucose-and tolbutamidestimulated insulin secretion. Also, since alloxan has been shown to produce an irreversible depolarization of the B-cell membrane [11 ] , stabilization of the membrane might explain DPH antagonism of the diabetogen.
It is unlikely, however, that membrane stabilization can account for the pancreatic effects of barbituric acid. Barbituric acid does not produce central nervous system depression and, to our knowledge, has never been reported to stabilize biological membranes.
Although our experiments demonstrate a barbituric acid-induced inhibition of glucose stimulated insulin release from isolated pancreatic islets, it is not possible to conclude that the in vivo effects of the chemical on carbohydrate metabolism are mediated through this mechanism alone. It is unlikely that barbituric acid antagonizes the peripheral action of insulin since the chemical did not reduce insulin-induced hypoglycemia in our mice.
Since phenobarbital possesses the unsubstituted ureido group and is known to stabilize biological membranes, its failure to influence the parameters studied in these experiments was surprising. These results are in agreement with those of Japundzic et al. [12] and Sato and Iwamoto [13] who reported that phenobarbital had no effect on blood glucose concentrations in rats and Gerhards et al. [14] , who reported that the drug has no effect on the hypoglycemic response to glycodiazine in rats, dogs or humans.
Malygina [8] , however, presented data to show that phenobarbital produces hypoglycemia in rabbits, while Stevens et al. [15] reported decreased glucose tolerance in rats. Yeung [ 16] observed phenobarbitalinduced hyperglycemia in new born humans.
Our discovery of the effects of barbituric acid on carbohydrate metabolism suggests a potential clinical a Six sets of isolated islets (3 per set) were exposed to 100 ~tg/ml barbituric acid and 3.0 mg/ml D-glucose. *A significant difference was detected at the 90 min interval (t9 < 0.01). Four sets of isolated islets (3 per set) were exposed to 100 Ixg/ml phenobarbital and 3.0 mg/ml D-glucose. No significant differences in IRI release were noted at any time interval. use for this chemical. Several therapeutic agents, such as the thiazide diuretics and diphenylhydantoin, are known to inhibit pancreatic insulin secretion. This action, which was initially considered to be an undesirable side-effect, has been employed in the treatment of hypoglycemia. The obvious disadvantage of these drugs lies in the fact that they possess well known pharmacological activities which, when the drugs are employed in the treatment of hypoglycemia, may be considered to be undesirable side-effects. Barbituric acid appears to be devoid of effects other than those on carbohydrate metabolism. We believe that further investigations into the potential use of barbituric acid in the treatment of functional hypoglycemia are warranted.
